This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Epidemiology of acute myeloid leukaemia

Authoring team

Although Acute Myeloid Leukaemia (AML) is rare, it is the commonest form of acute leukaemia in the adults.

In the western world AML is responsible for 25% of all leukaemias in adults

  • out of 7,600 people who are diagnosed with leukemias each year, around 2300 have AML (2)
  • affects around 3 out of 100,000 people in the UK (1)
  • incidence in adults in Europe is 5-8 cases/100 000/year (4)
  • the highest incidence of AML is seen in the U.S., Australia, and western Europe (3)

AML tends to show 2 peaks in incidence

  • in early childhood
    • the incidence peaks during the first year of life and then decrease steadily until the age of 4 years after which it remains relatively constant throughout the years of childhood and early adulthood (3)
  • in late adulthood
    • is rare before the age of 40 years but the incidence increases progressively thereafter with age (3)
    • is common in people over 65 years of age (2)
  • in USA between the years 2000 to 2003, the incidence rate of AML in people age <65 years was only 1.8 per 100,000 persons, while in people age >=65 years it was 17 per 100,000 persons (3)

Note:

  • a high incidence and also a poor prognosis of AML in the elderly appears to be partly associated with the increased incidence of myelodysplastic syndromes (MDS) with age (based on the fact that there is frequent progression of MDS to AML)

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.